Outcome Of Marketing Case Could Ripple Through Biotech, Pharma Companies
A federal case focuses on the question: Can a company market and sell its products for uses that federal regulators have not approved?
The Mercury News:
Silicon Valley Biotech Exec's Battle With The Federal Government
Bill Facteau made millions of dollars by selling a company that sold devices to treat sinus infections. But after the government accused him of questionable marketing practices surrounding one device, the Atherton biotech executive landed in federal court. Now his cautionary story has turned into a closely watched legal appeal that has consumer advocates, industry leaders and legal analysts debating a question that could have major consequences for Silicon Valley’s biotech and pharmaceutical companies: Should the First Amendment protect a firm’s right to market and sell its products for uses that federal regulators have not approved? (Seipel, 11/4)